PERSEPHONE Trial report from ASCO – Shorter duration adjuvant trastuzumab for HER2+ breast cancer non-inferior and with fewer cardiac side effects

The results of the PERSEPHONE trial, a phase III randomized, multicentre, non-inferiority clinical trial comparing 6 months of adjuvant trastuzumab to the current standard of 12 months, were presented at ASCO in May this year. Over 4,000 women with HER2-positive, early-stage breast cancer were randomised to 6 vs 12 months of adjuvant trastuzumab. The trial results show that the shorter duration is non-inferior and has a lower incidence of cardiac toxicity 1.

Read more PERSEPHONE Trial report from ASCO – Shorter duration adjuvant trastuzumab for HER2+ breast cancer non-inferior and with fewer cardiac side effects